Conflict of interest: None.
Brief Research Report
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies†
Article first published online: 2 DEC 2008
Copyright © 2008 Wiley-Liss, Inc.
American Journal of Hematology
Volume 84, Issue 3, pages 149–152, March 2009
How to Cite
Díez-Campelo, M., Pérez-Simón, J. A., Pérez, J., Alcoceba, M., Richtmon, J., Vidriales, B. and San Miguel, J. (2009), Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am. J. Hematol., 84: 149–152. doi: 10.1002/ajh.21340
- Issue published online: 25 FEB 2009
- Article first published online: 2 DEC 2008
- Accepted manuscript online: 2 DEC 2008 12:00AM EST
- Manuscript Accepted: 21 NOV 2008
- Manuscript Revised: 11 NOV 2008
- Manuscript Received: 6 AUG 2008
- CyL SA 16/02
- PROYECTO FIS RED G03/136. MDC GRANT OF ISCIII, 05/2180
This study evaluates the prognostic value of minimal residual disease (MRD) monitoring by multiparametric flow cytometry in 41 patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic transplantation. MRD assessment after transplant (day +100) allowed to discriminate different risk populations, being the most significant cut-off value for outcome level of MRD </≥10−3. Outcome was significantly better among patients with low (<10−3) versus high (≥10−3) MRD at day +100 after transplant. Thus, overall survival was 73% versus 25% at 4 years among patients with low versus high MRD at day +100 after transplant (P = 0.002); 74% of patients with low MRD were event free at 4 years as compared to 17% among patients with high MRD (P = 0.01). In multivariate analysis, MRD value as well as chronic GVHD significantly influenced outcome. In conclusion, MRD monitoring early post-transplant is an important tool for outcome prediction and should be considered in decision making after allogeneic transplantation. Am. J. Hematol. 2009. © 2008 Wiley-Liss, Inc.